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seem to be in better agreement with the IAEA TRS-398 values 
currently in use, than those of cylindrical chambers. 
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Purpose or Objective: Automated planning (AP) aims to 
simplify the treatment planning process by eliminating user 
variability. We performed a detailed plan comparison based 
on clinical objectives and dose-volume histogram (DVH) 
parameters in a group of stereotactic body radiation therapy 
(SBRT) lung cancer patients. 
 
Material and Methods: Between March 2012 and May 2015, 
55 lung cancer patients were treated with SBRT at our 
institution. A total dose of 60 Gy in 3 fractions was 
prescribed to the PTV (D95). For each patient, an IMRT plan 
was created using in-house developed optimization software 
by manually tweaking a set of optimization objectives during 
several iterations. Final dose calculation was performed in 
Pinnacle 9.8 (Philips Medical Systems Inc, USA). These plans 
are further referred to as the manual plans (MP). 
For each patient, an additional plan was created 
retrospectively using the Pinnacle 9.10 Auto-Planning 
software with a template representing the clinical objectives 
for the following structures: GTV, PTV, lungs minus GTV, 
spinal cord, esophagus, heart, aorta, trachea, main stem 
bronchus and chest wall. Using automatic optimization tuning 
methods, an automated plan (AP) was created for each 
patient using the same IMRT beam directions as for the MP. 
No additional manual tweaking whatsoever was performed. 
For all of the above-mentioned structures the following DVH 
parameters were included in our analysis: D99, D98, D95, 
D90, D50, D5, D2 (in which xx% of the PTV volume receives a 
dose of at least Dxx) and Dmean. For the organs at risk (OAR) 
V5, V10 and V20 were also included (in which Vxx is the 
volume receiving at least xx Gy). The acceptability of each 
plan was judged against our clinical objectives (result: pass, 
minor deviation or fail). Additionally, pairwise comparisons of 
the DVH parameters were performed using paired, two-sided 
t-tests between the MPs and APs. 
 
Results: Three APs failed in terms of our clinical objectives 
(1 plan: heart D2, 2 plans: chest wall D2), while 13 plans 
showed a minor deviation (12 plans: lungs minus GTV V20, 1 
plan: chest wall D2). None of the MPs failed our clinical 
objectives, but 9 also showed a minor deviation (8 plans: 
lungs minus GTV V20, 1 plan: PTV D99). The graph shows 
average values over all patients of the dose (in Gy) –volume 
(in %) parameters for which statistically significant (p < 0,05) 
differences were found between the MPs and APs. Top: GTV 
and PTV; bottom: clinical OAR objectives. All plans were 
normalized to PTV D95 = 60 Gy. 
 
 
Conclusion: Without user intervention, AP resulted in plans 
that comply with our clinical objectives for almost all 
patients. Some APs may require slight additional manual 
tweaking. From a statistical point of view, AP delivers 
significantly less dose to the OARs, while preserving target 
coverage. In the near future, all plans will be blindly 
evaluated by three experienced radiation oncologists to 
assess the clinical significance of the observed statistical 
differences. 
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Purpose or Objective: The ViewRay MRI-Co60 hybrid system 
(MRIdian) allows MRI based targeting, autosegmentation and 
direct planning for numerous anatomical districts. Our 
department is implementing this technology and, up to date, 
we are comparing planning procedures to our clinical 
standards in order to define which districts could take 
advantage from the use of the MRIdian technology. Aim of 
this investigation was to assess the impact of the MRIdian 
radiation therapy system through a planning analysis for 
rectal cancer treatments. 
 
Material and Methods: Ten sets of 3 plans (MRIdian, RapidArc 
and 5 beams sliding windows IMRT) were calculated for 10 
patients affected by locally advanced rectal cancer (cT3-cT4; 
cN0, cN+). ROIs were contoured on Eclipse TPS. RapidArc (6-
15 MV) and 5 beams (6-15 MV) sliding windows IMRT 
treatment plans were calculated on Eclipse according to our 
QA protocols. The PTV1 (CTV1+7 mm margin) was 
represented by tumor+1.5 cm margin craniocaudally and 
correspondent mesorectum, the PTV2 (CTV2 + 7 mm margin) 
by mesorectum in toto and pelvic nodes. The body, the bowel 
bag and the bladder were the OaR considered. The 
prescribed dose for PTV2 was 45 Gy and 55 Gy for PTV1 
through simultaneous integrated boost. The PTV V95 and 
OaRs QUANTEC dose constraints on the DVHs and Wu’s 
homogeneity indexes (HI) were considered for the QA of the 
plans. The structure sets were then uploaded on the MRIdian 
TPS and Co60 step and shoot IMRT plans (7 groups of 3 fields) 
were calculated. The DHVs and HIs were then compared to 
the RapidArc and IMRT plans in order to evaluate MRIdian’s 
performances. 
 
Results: MRIdian showed a better HI when compared to the 
other techniques for PTV1, while this advantage could not be 
appreciated for PTV2, even if a better PTV2 V100 (45 Gy) was 
observed. Comparable mean doses for the bladder were 
registered, while a higher bowel V45 was observed (even if 
still in the constraints limits). Low dose body V5 was higher 
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for the MRIdian plans. The mean results and the standard 
deviations are summarized in the table. 
 
 
 
Conclusion: A comparable PTV dose coverage between the 3 
plans was found for rectal cancer, with a HI advantage for 
the PTV1 for the MRIdian plan. Differences were described 
for OaRs, especially for low dose areas (V5 Body). MRIdian 
allowed to reach dosimetrical goals comparable to RapidArc 
and IMRT gold standards. The evaluation of a possible 
reduction in PTV margin and a proper target coverage by MRI 
based gating will be analyzed when the system will become 
operative at Gemelli ART.  
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Purpose or Objective: The cervix-uterus shows large day-to-
day variation in position and size, mainly depending on 
bladder and rectum filling. Image-guided adaptive 
radiotherapy with a library of plans (LOP) is a strategy to 
mitigate these large variations, resulting in less dose to 
organs at risk (OAR) compared to the use of a single plan with 
a population-based PTV margin. A further reduction of OAR 
dose can be achieved using proton therapy. However, it is 
challenging to achieve a target coverage that is robust for 
range and position uncertainties. The aim of this study is to 
compare target coverage of robustly optimized photon and 
proton therapy plans using a LOP adaptive strategy for 
cervical cancer. 
 
Material and Methods: Five cervical cancer patients treated 
with photon therapy were retrospectively included. For each 
patient a full and empty bladder planning CT and weekly 
repeat CTs were acquired. Depending on the magnitude of 
cervix-uterus motion, one to three ITV sub ranges were 
generated by interpolation of the CTV delineations on full 
and empty bladder CT. Target and OARs were delineated on 
all repeat CTs. Robustly optimized photon (VMAT) library 
plans and proton (IMPT) library plans were generated with a 
prescribed dose of 46 Gy in 23 fractions to the ITV. For robust 
optimization, a position uncertainty of 0.8 cm was applied; 
for protons 3% range uncertainty was included as well. The 
plans were required to have sufficient target coverage 
(V95%>99%) for both the nominal scenario and twelve 
scenarios with different range and position errors. Both for 
protons and photons the actual delivered dose was simulated. 
Repeat CTs were registered to the full bladder planning CT 
using bony anatomy, the best fitting library plan was selected 
and the dose was recalculated. The DVH for the whole 
treatment was estimated by adding and scaling DVHs. The 
target coverage was evaluated for the total CTV as well as 
the CTVs of the corpus uteri, cervix, vagina and elective 
lymph nodes. 
 
Results: For the total CTV, on average, the V95% for the 
whole treatment was 99.9% (range 97.3%-99.8%) for photons 
and 96.3% (93.5%-98.1%) for protons. The V95% of the corpus 
uteri was 95.7% (86.3%-99.9%) and 88.7% (68.4%-99.9%) for 
photons and protons, respectively. Figure 1 shows a repeat 
CT with insufficient target coverage both for photons and 
protons. The elective lymph nodes received sufficient dose 
with photons, on average, V95% was 99.1% (98.1%-99.8%). 
With protons this volume decreased to 96.2%(94.9%-98.8%). 
For the cervix and vagina no differences between the use of 
photons and protons were observed. 
 
 
 
Conclusion: The robustly optimized proton therapy plans did 
not result in an adequate target coverage for all patients for 
the realistic robustness parameters used. For some cases the 
used LOP strategy is not sufficient to cope with the large 
movements of the cervix-uterus for both modalities. The 
impact of underdosing is larger using protons than using 
photons. 
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Purpose or Objective: Dose calculation is currently based on 
the density map provided by CT. However, for delineation of 
the prostate gland and organs at risk T2-weighted MR imaging 
is the gold standard. Dose calculation based on MR 
information would remove the need for a CT scan and avoid 
the uncertainty related to registration of the images. Pseudo-
CT generation from MR scans has recently become available. 
This study investigates the validity of dose calculation based 
on pseudo CT created with commercial software (MR for 
Calculating ATtenuation – MRCAT) compared to standard CT 
based dose calculation. 
 
Material and Methods: Seven high risk prostate cancer 
patients were MR and CT scanned. The clinical, curatively 
intended treatment (78 Gy in 39 Fx) using single arc VMAT 
was based on the conventional CT. From the MR scan pseudo-
CT were created using MRCAT (Philips, Helsinki, Finland). To 
eliminate dose comparison uncertainties related to patient 
positioning differences between CT and MR rigid CT-MR 
